Trial Information
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
